
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Washington - The optimum doses of biologic treatments for psoriasis may be higher than previously believed, according to Mark Lebwohl, M.D., professor and chairman, department of dermatology, Mt. Sinai School of Medicine.






